Last updated on March 2020

Study to Assess the Safety Tolerability Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age


Brief description of study

A Phase 1/2, Open-label, Multicenter, Non-randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Pediatric Patients from Birth to Less than

1 Year of Age with X-linked Hypophosphatemia (XLH)

Clinical Study Identifier: NCT04188964

Find a site near you

Start Over